Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.

Petros Grivas,Elizabeth R Plimack,Arjun V Balar,Daniel Castellano,Peter H O'Donnell,Joaquim Bellmunt, Thomas Powles,Noah M Hahn,Ronald de Wit,Dean F Bajorin,Misoo C Ellison,Tara L Frenkl,James L Godwin,Jacqueline Vuky

European Urology Oncology（2020）

引用 30|浏览67

暂无评分

摘要

Pembrolizumab is effective and well tolerated in cisplatin-ineligible senior patients with advanced urothelial cancer, including those with poor performance status. Tumor response and outcomes were not impacted by poor performance status and/or older age.

查看译文

关键词

Aged,Bladder cancer,Checkpoint inhibitor,Cisplatin ineligible,Immunotherapy,Programmed death 1,Pembrolizumab,Platinum ineligible,Poor performance status,Urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要